Literature DB >> 8666151

Multiple lipoprotein abnormalities in type I diabetic patients with renal disease.

P H Groop1, T Elliott, A Ekstrand, A Franssila-Kallunki, R Friedman, G C Viberti, M R Taskinen.   

Abstract

The aim of this study was to characterize abnormalities of triglyceride-rich apolipoprotein (apo) B-containing lipoproteins in type I diabetic patients with elevated albumin excretion rates (AERs). Sixty-four patients (31 men, 33 women) with normoalbuminuria (AER <20 microg/min), 52 (35 men, 17 women) with microalbuminuria (AER 20-200 microg/min), and 37 (17 men, 20 women) with albuminuria (AER >200 microg/min) and 56 healthy control subjects matched for age and body weight were studied. The major finding was increased mass concentrations of the highly atherogenic intermediate-density lipoprotein fraction in patients with microalbuminuria (P < 0.05) and albuminuria (P < 0.05), compared with those with normoalbuminuria. Triglyceride, free cholesterol, cholesterol ester, and phospholipid concentrations in the VLDL, intermediate-density lipoprotein, and LDL (P < 0.05-0.01), as well as total cholesterol, total triglyceride, and apoB concentrations were higher in patients with renal disease than in those without. Notably, there were no differences between patients with microalbuminuria and albuminuria. Only minor compositional changes could be detected. Postheparin plasma lipoprotein lipase (LPL) activities were identical, but hepatic lipase activities were higher in microalbuminuric and albuminuric patients than in normoalbuminuric patients (P < 0.01). LPL activity and VLDL1, (Sf 60-400) (r = -0.528; P < 0.001) and VLDL2 (Sf 20-60) mass concentrations (r = -0.471; P < 0.001) were negatively related. In conclusion, in type I diabetic patients with early renal disease, there are multiple lipoprotein changes, which are potentially atherogenic and may contribute to the excess of macrovascular complications seen in such patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666151     DOI: 10.2337/diab.45.7.974

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  14 in total

Review 1.  Is it possible to predict diabetic kidney disease?

Authors:  S M Thomas; G C Viberti
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

Review 2.  Cardiovascular disease risk in young people with type 1 diabetes.

Authors:  Janet K Snell-Bergeon; Kristen Nadeau
Journal:  J Cardiovasc Transl Res       Date:  2012-04-12       Impact factor: 4.132

Review 3.  Lipids and diabetic nephropathy.

Authors:  Rey F Rosario; Sharma Prabhakar
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

4.  A retrospective study on the influence of apolipoprotein e and serum lipids in progressive renal failure.

Authors:  L Roussos; Peter-Nilsson Ehle; Claes-Henrik Florén
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

5.  Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes.

Authors:  S D Sibley; J E Hokanson; M W Steffes; J Q Purnell; S M Marcovina; P A Cleary; J D Brunzell
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

6.  Relationship between lipid profiles and kidney function in patients with type 1 diabetes.

Authors:  N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; O Heikkilä; K Pettersson-Fernholm; M-R Taskinen; P-H Groop
Journal:  Diabetologia       Date:  2007-11-10       Impact factor: 10.122

7.  Association of remnant cholesterol with chronic kidney disease in middle-aged and elderly Chinese: a population-based study.

Authors:  Pijun Yan; Yong Xu; Ying Miao; Xue Bai; Yuru Wu; Qian Tang; Zhihong Zhang; Jiong Yang; Qin Wan
Journal:  Acta Diabetol       Date:  2021-06-28       Impact factor: 4.280

8.  Renal functional reserve in patients with Type 1 diabetes mellitus.

Authors:  Jelka Zaletel; Darko Cerne; Katarina Lenart; Sabine Zitta; Günther Jürgens; Willibald Estelberger; Andreja Kocijancic
Journal:  Wien Klin Wochenschr       Date:  2004-04-30       Impact factor: 1.704

Review 9.  Cost-effective strategies in the prevention of diabetic nephropathy.

Authors:  Jonathan D Rippin; Anthony H Barnett; Stephen C Bain
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (the FinnDiane Study).

Authors:  Ville-Petteri Mäkinen; Carol Forsblom; Lena M Thorn; Johan Wadén; Kimmo Kaski; Mika Ala-Korpela; Per-Henrik Groop
Journal:  Cardiovasc Diabetol       Date:  2009-10-06       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.